<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Obstet Gynecol</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Obstet Gynecol</journal-id><journal-id journal-id-type="publisher-id">IDOG</journal-id><journal-title-group><journal-title>Infectious Diseases in Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="ppub">1064-7449</issn><issn pub-type="epub">1098-0997</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18288237</article-id><article-id pub-id-type="pmc">2216064</article-id><article-id pub-id-type="doi">10.1155/2007/35387</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Phase I Trial of a <italic>Lactobacillus crispatus</italic> Vaginal Suppository for Prevention of Recurrent Urinary Tract Infection in Women</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Czaja</surname><given-names>Christopher A.</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Stapleton</surname><given-names>Ann E.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Yarova-Yarovaya</surname><given-names>Yuliya</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Stamm</surname><given-names>Walter E.</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">
Division of Allergy and Infectious Diseases, 
University of Washington School of Medicine, Seattle, WA 98195, USA</aff><author-notes><corresp id="cor1">*Christopher A. Czaja: <email>czajac@njc.org</email></corresp></author-notes><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2007</year></pub-date><volume>2007</volume><elocation-id>35387</elocation-id><history><date date-type="received"><day>15</day><month>6</month><year>2007</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Christopher A. Czaja et al.</copyright-statement><copyright-year>2007</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Objectives</italic>: We performed a phase I trial to assess the safety and tolerance of a <italic>Lactobacillus</italic> vaginal suppository for prevention of recurrent UTI.
<italic>Methods</italic>: Premenopausal women with a history of recurrent UTI were randomized to use <italic>L. crispatus</italic> CTV-05 or placebo vaginal suppositories daily for five days.
<italic>Results</italic>: 30 women were randomized (15 to <italic>L. crispatus</italic> CTV-05). No severe adverse events occurred. Mild to moderate vaginal discharge and genital irritation were reported by women in both study arms. Seven women randomized to <italic>L. crispatus</italic> CTV-05 developed pyuria without associated symptoms. Most women had high concentrations of vaginal 
<inline-formula><mml:math id="M1"><mml:mrow><mml:msub><mml:mtext>H</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>-producing lactobacilli before randomization. <italic>L. crispatus</italic>, 
<italic>L. jensenii</italic>, and <italic>L. gasseri</italic> were the most common 
<italic>Lactobacillus</italic> species identified, with stable prevalence over time.
<italic>Conclusions: L. crispatus</italic> CTV-05 can be given as a vaginal suppository with minimal sideeffects to healthy women with a history of recurrent UTI. Mild inflammation of the urinary tract was noted in some women.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. INTRODUCTION</title><p>Urinary tract infections (UTIs)
affect millions of women each year, with an annual societal cost of billions of
dollars [<xref rid="B1" ref-type="bibr">1</xref>]. Importantly, more than one quarter of women with a UTI will have a
recurrent infection within six months [<xref rid="B2" ref-type="bibr">2</xref>].
There are few established options for prevention of UTI other than the
use of prophylactic antibiotics [<xref rid="B3" ref-type="bibr">3</xref>].
However, resistance to commonly used antibiotics is increasing among
bacterial cystitis isolates [<xref rid="B4" ref-type="bibr">4</xref>].
Therefore, effective nonantibiotic methods of prevention are
needed. One potential alternative may be
a lactobacillus probiotic.</p><p>A growing body of evidence suggests that vaginal H<sub>2</sub>0<sub>2</sub>-producing
lactobacilli may have a protective effect against urogenital infections,
including UTI [<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>]. It is hypothesized
that lactobacilli prevent uropathogen colonization of the vagina, a necessary
step in ascending infection of the bladder.
Several clinical trials have demonstrated that certain <italic>Lactobacillus</italic> species, mainly <italic>L. rhamnosus</italic> and <italic> L. fermentum</italic>, can be given orally or vaginally with resulting
colonization of the vagina, reduction in vaginal coliform counts, and even
reduction in UTI recurrence 
[<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. Specific
strains were chosen for their abilities to produce H<sub>2</sub>0<sub>2</sub>, adhere to uroepithelial cells, interfere with uropathogen attachment and growth, and persist in the vagina [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>].
The most frequently existing vaginal <italic>Lactobacillus</italic> species, <italic>L.
crispatus</italic> [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>], also produces H<sub>2</sub>0<sub>2</sub> and possesses the adherence and inhibitory qualities essential for a good probiotic
candidate [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>].</p><p>
<italic>L. crispatus</italic> strain CTV-05 has been
developed as a vaginal suppository (LACTIN-V) for the prevention of recurrent
UTI in women. <italic>L. crispatus</italic> CTV-05 is
highly adherent to vaginal epithelial cells [<xref rid="B24" ref-type="bibr">24</xref>], and when given as a suppository
can colonize the vagina [<xref rid="B25" ref-type="bibr">25</xref>].
Furthermore, <italic>L. crispatus</italic> CTV-05 has been reported to have a specific DNA fingerprint that distinguishes
it from endogenous vaginal lactobacilli [<xref rid="B25" ref-type="bibr">25</xref>].
To further evaluate the safety of this new formulation of <italic>L. crispatus</italic> CTV-05 and its effect on
the vaginal microbial flora, we conducted a phase I, randomized, double-blind,
placebo-controlled trial of vaginal <italic>L.
crispatus</italic> CTV-05 in premenopausal women with a history of recurrent UTI.</p></sec><sec id="sec2"><title>2. SUBJECTS AND METHODS</title><statement id="head1"><title>Participants</title><p>We recruited premenopausal women aged 18&#x02013;35
years with a history of three or more uncomplicated UTIs diagnosed in the past
year, or two uncomplicated
UTIs diagnosed in the past six months, from (student health center, University
of Washington, Wash, USA.) Additional eligibility requirements
included regular menstrual cycles or amenorrhea for at least six months
secondary to use of a hormonal contraceptive, a normal Pap smear documented in
the last year or at the baseline clinic visit, abstinence
from sexual activity or participation in
a mutually monogamous sexual relationship, use of birth control, agreement not
to use other intravaginal products, agreement not to have sexual intercourse or
use tampons between the baseline and first follow-up visit, and capability to
understand English and provide informed consent. Exclusion criteria included history of
urologic abnormality, recent urologic surgery or urinary catheterization,
history of complicated pyelonephritis or renal calculi, hysterectomy, recent sexually
transmitted infection (STI) or bacterial vaginosis, risk factors for STI and
HIV, history of recurrent genital herpes, menses anticipated within ten days, pregnancy,
lactation, recent antibiotic or antifungal use, diabetes or other immunocompromised state, drug
or alcohol abuse, use of the (NuvaRing), prior use of the study drug or allergy
to any of its components, and abnormal initial pelvic examination. The study was approved by (Institutional
Review Board (IRB), University of Washington, Wash,
USA.)</p></statement><statement id="head2"><title>Study design</title><p>Subjects were randomized in a double-blinded
fashion to <italic>L. crispatus</italic> CTV-05 at a
dose of 5 &#x000d7; 10<sup>8</sup> colony forming units
(cfu) or placebo vaginal suppository to be inserted daily for five days. <italic>L. crispatus</italic> CTV-05 and placebo
suppositories were similar in appearance and consisted of a preservation matrix
and maltodextran. Both were prepackaged
by the manufacturer (Osel, Inc., Palo Alto,
Calif, USA) according to a randomization
schedule and supplied to the study site sequentially labeled with a subject
number.</p><p>Subjects
were seen at three clinic visits over a period of one month. At the first (baseline) visit, eligible subjects
provided informed consent before undergoing a structured medical and
gynecologic history and physical examination.
They provided urine, vaginal, and cervical specimens. Subjects inserted the first dose of study
drug in the clinic and were instructed to record any symptoms occurring during
the first week of study on a prepared diary card. Subjects were seen in follow-up 6&#x02013;8 days (1-week)
visit and 26&#x02013;34 days (4-week) visit after enrollment. During these visits, new symptoms, new
urogenital infections, and any changes in clinical history were recorded. Follow-up visits were otherwise similar to the
baseline visit. Finally, subjects were
contacted by telephone six months after enrollment to assess symptoms,
pregnancy, new diagnoses, or major medical events.</p><p>Laboratory
testing included urine dipstick testing, urinalysis, urine culture, vaginal
fluid wet preparation slides, gram stains, and culture for facultative isolates
and <italic>Lactobacillus</italic> species at all
visits. Repetitive element
sequence-based polymerase chain reaction (rep-PCR) for <italic>L. crispatus</italic> CTV-05 was performed on three lactobacillus colonies
from culture at each visit [<xref rid="B25" ref-type="bibr">25</xref>]. Urine
pregnancy testing was performed at the baseline and 4-week visits. Testing for <italic>Neisseria gonorrhoeae</italic> and <italic>Chlamydia
trachomatis</italic> by DNA amplification was done at the baseline visit.</p><p>A
sample size of 30 was chosen to evaluate the primary outcome of safety as
assessed through self-reported symptoms, physical exam findings, and laboratory
studies. Secondary outcomes included
shifts in the vaginal flora assessed by vaginal culture and vaginal
colonization with <italic>L. crispatus</italic> CTV-05
assessed by rep-PCR. The Fisher exact
test was used to test statistical significance.</p></statement></sec><sec id="sec3"><title>3. RESULTS</title><p>Thirty women were randomized (15 to <italic>L. crispatus</italic> CTV-05). All subjects
took the five planned doses of study drug.
Two women randomized to <italic>L.
crispatus</italic> CTV-05 completed treatment over six days, and one woman
randomized to placebo used six suppositories over six days. All women remained on study through the
4-week visit (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Baseline
characteristics of subjects were similar in the two treatment groups (<xref ref-type="table" rid="tab1">Table 1</xref>). The majority of women were young, white,
healthy, university students in their 20s.
The median number of UTIs in the last year was three. Screening tests for pregnancy and STI were
negative for all subjects.</p><statement id="head3"><title>Safety</title><p> There were no severe adverse events. Mild to moderate adverse events were
relatively common, however. Of those
felt by the investigators to be related to study drug use, abnormal vaginal
discharge was the most frequently occurring, followed by external genital
irritation and vaginal candidiasis (<xref ref-type="table" rid="tab2">Table 2</xref>). These adverse events occurred with
similar or greater frequency in women randomized to placebo as compared to women
randomized to <italic>L. crispatus</italic> CTV-05. Three women reporting vaginal candidiasis also
reported multiple prior episodes in the preceding 12 months. Two women randomized to <italic>L. crispatus</italic> CTV-05 reported episodes of cystitis during the
study.</p><p>All subjects completed a diary card of symptoms that occurred during the period of
study drug insertion. Recorded symptoms generally
confirmed the reported adverse events and were similar to symptoms reported at the
1-week clinic visit (below). These
symptoms occurred with similar frequency in each treatment arm.</p><p>Abnormal
vaginal discharge was the symptom most frequently reported by subjects at
clinic visits following study drug use (<xref ref-type="fig" rid="fig2">Figure 2</xref>). While no women reported abnormal
vaginal discharge at baseline, six randomized to <italic>L. crispatus</italic> CTV-05 and five randomized to placebo reported abnormal
vaginal discharge at the 1-week visit. Abnormal
discharge was less frequently reported at the 4-week visit. External genital or vaginal irritation was
also reported by six women in each treatment arm at follow-up visits. Vaginal odor was reported at the 1-week visit
by one woman randomized to <italic>L. crispatus</italic> CTV-05,
and at the 4-week visit by two women randomized to placebo. Dysuria was reported by one woman randomized
to <italic>L. crispatus</italic> CTV-05 at the 1-week visit
and by one woman randomized to placebo at the 1- and 4-week visits. Headache, abdominal or pelvic cramps/abdominal
pain, and low back pain were frequently reported at baseline as well as at
follow-up visits. There were no
significant differences in reported symptoms at any visit between women in the
two treatment arms.</p><p>Physical
exam findings were benign in both treatment arms. External genital erythema was found at the 1-
and 4-week visits in more women randomized to <italic>L. crispatus</italic> CTV-05 than in women randomized to placebo (4 versus 1, <inline-formula><mml:math id="M2"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.33</mml:mn></mml:mrow></mml:math></inline-formula>). Moderate-to-profuse vaginal
discharge was frequently found in women from both treatment arms during
follow-up examinations
(12 versus 8, <italic>P</italic> = 1.00), though this finding was also often apparent at the
baseline visit (6 women in each arm).
One woman randomized to placebo had vaginal erythema noted at 1 week. No cervical, urethral, uterine, or adnexal
abnormalities were noted.</p><p>Seven
(47%) women randomized to <italic>L. crispatus</italic> CTV-05 had nine episodes of pyuria with a urine white blood cell count &#x02265;8 per mm<sup>3</sup> [<xref rid="B26" ref-type="bibr">26</xref>] (range 8&#x02013;203) during a follow-up clinic visit (<xref ref-type="table" rid="tab3">Table 3</xref>). None of these women
had pyuria at baseline. In contrast, none
of the women randomized to placebo had pyuria at 1 or 4 weeks (<italic>P</italic> = .01). Pyuria was positively correlated with urine
leukocyte-esterase test results (Spearman <italic>r</italic> = 0.57, <inline-formula><mml:math id="M3"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:mrow></mml:math></inline-formula>). There
were no significant associations with vaginal or urinary symptoms or exam
findings. Microbes isolated from the
urine of women in the <italic>L. crispatus</italic> CTV-05 arm with pyuria included
mixed gram-positive organisms (6), lactobacillus (3), <italic>E. coli</italic> (1), enterococcus (1), group B streptococcus (1), and yeast
(1). One subject had a negative urine
culture, and none had symptomatic infection.
Lactobacillus and mixed gram-positive rods were isolated at 10<sup>3</sup>-10<sup>4</sup> cfu/ml from more women with pyuria (50% and 75%) than without (19% and 46%,
resp.) at the 1-week visit (<inline-formula><mml:math id="M4"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.22</mml:mn></mml:mrow></mml:math></inline-formula> for lactobacillus, <inline-formula><mml:math id="M5"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.60</mml:mn></mml:mrow></mml:math></inline-formula> for
mixed gram-positive rods) but not at the 4-week visit. None of the other isolated organisms was found
at a significantly increased frequency in women randomized to <italic>L. crispatus</italic> CTV-05 versus placebo or
in women with pyuria compared to those without pyuria at any visit. Two women randomized to <italic>L. crispatus</italic> CTV-05 and one randomized to placebo had hematuria at
the 4-week visit (<inline-formula><mml:math id="M6"><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:math></inline-formula>30 red blood cells per mm<sup>3</sup>).</p><p>Nine women in the <italic>L. crispatus</italic> CTV-05 arm and ten in the
placebo arm completed the six-month follow-up telephone call. None reported pregnancy, and no major health
problems occurred. Four women in the <italic>L. crispatus</italic> CTV-05 arm and one in the
placebo arm reported one or more episodes of cystitis.</p></statement><statement id="head4"><title>Effects on vaginal flora</title><p>28 of 30 women had vaginal
colonization with H<sub>2</sub>0<sub>2</sub>-producing
lactobacilli at baseline and all follow-up visits (<xref ref-type="table" rid="tab4">Table 4</xref>). Two women
randomized to placebo had no vaginal H<sub>2</sub>0<sub>2</sub>-producing
lactobacilli detected at any clinic visit.
One of these women had large quantities of <italic>Gardnerella</italic> and <italic>Bacteroides</italic> species morphotypes on gram stain. Cultures
from women with H<sub>2</sub>0<sub>2</sub>-producing
lactobacilli yielded heavy (4+) growth.</p><p>Vaginal
cultures from five women in each treatment arm yielded <italic>E. coli</italic> from one or more clinic visits. <italic>E. coli</italic> was isolated from vaginal cultures taken at the 1- and 4-week visits from 4
women randomized to <italic>L. crispatus</italic> CTV-05 and from one women randomized to placebo (<inline-formula><mml:math id="M7"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.33</mml:mn></mml:mrow></mml:math></inline-formula>). No inverse association between vaginal
colonization with H<sub>2</sub>0<sub>2</sub>-producing
lactobacilli and vaginal colonization with <italic>E.
coli</italic> was detected. Vaginal cultures
frequently yielded <italic>Candida</italic> at baseline
as well as follow-up visits.</p></statement><statement id="head5"><title>Rep-PCR</title><p>Using rep-PCR, <italic>L. crispatus</italic> CTV-05 was detected in the vaginas of four women
randomized to <italic>L. crispatus</italic> CTV-05
(three women at each clinic visit). Three
women had a positive assay for <italic>L.
crispatus</italic> CTV-05 detected at the baseline visit before administration of the
study drug. No women randomized to
placebo had a positive assay at any visit (<italic>P</italic> = .22 each visit).</p><p>We
compared our rep-PCR results (<xref ref-type="fig" rid="fig3">Figure 3</xref>)
to previously published rep-PCR patterns [<xref rid="B25" ref-type="bibr">25</xref>] in order to identify the
bacterial species. At baseline, 80% of
subjects had <italic>L. crispatus</italic>, 37% had <italic>L. jensenii</italic>, 17% had <italic>L. gasseri</italic>, and 27% had other <italic>Lactobacillus</italic> species detected in
vaginal culture. The following
combinations of <italic>Lactobacillus</italic> species
were found: <italic>L. crispatus</italic> (27%), <italic>L. crispatus</italic> and <italic>L. jensenii</italic> (20%), <italic>L.
crispatus</italic> and <italic>L. gasseri</italic> (7%), <italic>L. crispatus</italic> and other <italic>Lactobacillus</italic> species (13%), <italic>L. crispatus</italic>, <italic>L. jensenii</italic>, and <italic>L. gasseri</italic> (3%), <italic>L. crispatus</italic>, <italic>L. jensenii</italic>, and other <italic>Lactobacillus</italic> species (7%), <italic>L. crispatus</italic>, <italic>L. gasseri</italic>, and other <italic>Lactobacillus</italic> species (3%), <italic>L. jensenii</italic> (7%), <italic>L. gasseri</italic> (3%), other <italic>Lactobacillus</italic> species (3%), and no <italic>Lactobacillus</italic> (7%). The prevalences of individual species were
relatively stable over time (<xref ref-type="fig" rid="fig4">Figure 4</xref>). There were no significant differences in <italic>Lactobacillus</italic> species prevalence between
subjects in the two treatment arms with the exception of <italic>L. gasseri</italic> at the 1-week visit (<italic>P</italic> = .02).</p></statement></sec><sec id="sec4"><title>4. DISCUSSION</title><p>In phase I, placebo-controlled trial, use of a <italic>L. crispatus</italic> CTV-05 vaginal suppository, 
for the prevention of recurrent UTI was well tolerated with minimal side effects. There were no serious adverse events, and
despite the occurrence of abnormal vaginal discharge and external genital or
vaginal irritation in several women, compliance was high. These mild to moderate symptoms appear to be
secondary to the act of suppository use or a reaction to the preservation
matrix rather than a consequence of <italic>L.
crispatus</italic> CTV-05 as they occurred with similar frequency among women in
each treatment arm. Several women also
reported vaginal candidiasis. However,
given the frequency of recurrent vaginal candidiasis experienced by subjects
prior to enrollment and the prevalence of <italic>Candida</italic> in baseline vaginal cultures, the relationship of this condition to study drug
use is not compelling.</p><p>
<italic>L. crispatus</italic> CTV-05 use was associated
with pyuria (detected by microscopy and urine leukocyte-esterase) in seven women
at either the 1- or 4-week visits (<italic>P</italic> = .04 at 4 weeks). Pyuria was not associated with urogenital
symptoms, exam findings, or symptomatic UTI.
While lactobacillus was not isolated from the urine during every episode
of pyuria, it is possible that some lactobacilli were misclassified as mixed gram-positive
rods, as both were more frequently found in women with pyuria than in women
without. Our data suggest that vaginal
instillation of <italic>L. crispatus</italic> CTV-05 induces
a mild inflammatory response in the bladder or vaginal mucosa of some subjects
without causing prolonged urogenital infection.
The importance of this phenomenon with respect to safety or potential efficacy
is unclear. It is possible that induction of an asymptomatic inflammatory
response by lactobacilli protects against uropathogen colonization of the
vagina or infection in the bladder [<xref rid="B27" ref-type="bibr">27</xref>].</p><p>Limited
existing data from prior studies suggest that <italic>L. crispatus</italic> therapy is safe.
Women surveyed after participation in a clinical trial of a vaginal
capsule formulation of <italic>L. crispatus</italic> CTV-05
for treatment of bacterial vaginosis rarely reported adverse effects, and those
reported were largely related to a perceived difference in vaginal
discharge. Satisfaction with the vaginal
capsule was high [<xref rid="B28" ref-type="bibr">28</xref>]. No adverse effects were reported in a pilot study of <italic>L. crispatus</italic> CTV-05 given
intravaginally to a small group of healthy women [<xref rid="B25" ref-type="bibr">25</xref>]. Nine women with a history of recurrent UTI
reported no adverse effects when given <italic>L.
crispatus</italic> strain GA198332 as a vaginal suppository every other day for one
year [<xref rid="B29" ref-type="bibr">29</xref>]. Studies of other probiotic
strains of <italic>Lactobacillus</italic> have
indicated that they can be given to women safely with minimal or no side
effects [<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. To our knowledge, pyuria
resulting from vaginal instillation of <italic>Lactobacillus</italic> has not been previously reported, and should be evaluated further in future
studies.</p><p>We
did not see an effect of <italic>L. crispatus</italic> CTV-05 use on vaginal <italic>Lactobacillus</italic> growth. However, most study participants had heavy
vaginal growth of H<sub>2</sub>O<sub>2</sub>-producing
lactobacilli at baseline, making detection of subsequent changes difficult. Data from a pilot study indicated that <italic>L. crispatus</italic> CTV-05 did not displace other
endogenous vaginal lactobacilli. Vaginal
colonization was most successful in women lacking vaginal H<sub>2</sub>O<sub>2</sub>-producing
lactobacilli at the outset, suggesting that a lactobacillus probiotic may be
most effective at establishing vaginal colonization in women with abnormal
flora, such as those with bacterial vaginosis or recurrent UTI [<xref rid="B25" ref-type="bibr">25</xref>].</p><p>To our knowledge, our study represents the first attempt to use rep-PCR to identify the genetic fingerprint of the probiotic strain <italic>L. crispatus</italic> CTV-05 in a larger-scale clinical study. Although none of the placebo recipients were
colonized with lactobacillus strains having the characteristic rep-PCR pattern of <italic>L. crispatus</italic> CTV-05 at any time, three
women randomized to <italic>L. crispatus</italic> CTV-05 had at least one isolate in their vaginal culture at baseline that bore
the characteristic fingerprint. Therefore,
colonization of the vagina following suppository administration was difficult to demonstrate. As there are no
large-scale surveys of the prevalence and distribution of lactobacilli bearing this fingerprint, we do not know whether the rep-PCR technique failed to
distinguish <italic>L. crispatus</italic> CTV-05 from
other genetically closely related strains of <italic>L. crispatus</italic> naturally colonizing the vagina at baseline, or
whether the identical strain was prevalent in our study population. Of note, subjects in our study had a much
higher prevalence of vaginal H<sub>2</sub>O<sub>2</sub>-producing
lactobacilli in baseline vaginal cultures than found in previous studies [<xref rid="B25" ref-type="bibr">25</xref>]. By comparing our rep-PCR results to previous
published rep-PCR patterns [<xref rid="B25" ref-type="bibr">25</xref>], we characterized lactobacillus isolates at the
species level and found <italic>L. crispatus</italic>, <italic>L. jensenii</italic>, and <italic>L. gasseri</italic> to be the most prevalent species, with relatively stable
prevalences over time. Our prevalence
data are consistent with what has been previously documented [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Additional tests are under way to compare
quantitative PCR results for <italic>L. crispatus</italic> in women before and after the introduction of active suppositories or placebo.</p><p>Our study was not
designed nor statistically powered to evaluate the effect of <italic>L. crispatus</italic> CTV-05 on the rate of UTI
recurrence. Therefore, it is difficult
to interpret the report of cystitis in two women randomized to <italic>L. crispatus</italic> CTV-05. Other small studies have suggested that use of
vaginally administered <italic>L. crispatus</italic> may
be associated with a lower rate of UTI recurrence [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B29" ref-type="bibr">29</xref>].</p><p>The major strengths
of our study include the placebo-controlled, randomized study design, excellent
compliance, and extensive and complete followup. Use of a study diary provided finer details
of our subjects&#x02019; experiences that confirmed adverse events and symptoms
reported from memory at clinic visits. Weaknesses
that should be mentioned include the inability to accurately document vaginal
colonization with the probiotic strain, and the inherent lack of statistical
power due to the small sample size typical of phase I studies. We are currently conducting a phase II trial
that will have more power to clarify some of the issues raised in this
study.</p><p>In
conclusion, <italic>L. crispatus</italic> CTV-05 is
well tolerated when given as a vaginal suppository to healthy women with a
history of recurrent UTI. Mild to
moderate side effects related to suppository use occur but do not affect
compliance. <italic>L. crispatus</italic> CTV-05 may
cause mild asymptomatic inflammation of the lower urinary tract. Timing of administration and efficacy in
preventing recurrent cystitis should be evaluated further in larger studies.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>
The authors
thank May Antonio and Sharon Hillier (University of
Pittsburgh, Pa, USA) for advice regarding the Rep PCR assay and Osel,
Inc. (Palo Alto, Calif, USA)
for supplying the <italic>L. crispatus</italic> CTV-05
vaginal suppositories and placebo.&#x000a0; They also
thank Marsha Cox and Sheila Manuguid for their work in the UTI research
laboratory at the University of Washington, and Niki DeShaw and Ellen M. Cassen for
their work in the UTI research clinic, Hall Health Primary Care Center,
University of Washington. The study was funded by DK
PO1 053369 (WES) and R01DK070906 (AES). The authors have no disclosures. While Osel, Inc. (Palo Alto, Calif, USA) provided the <italic>L. crispatus</italic> CTV-05
vaginal suppositories, the design, conduct, and analysis of the study were completed
independently by the investigators</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxman</surname><given-names>B</given-names></name><name><surname>Barlow</surname><given-names>R</given-names></name><name><surname>D'Arcy</surname><given-names>H</given-names></name><name><surname>Gillespie</surname><given-names>B</given-names></name><name><surname>Sobel</surname><given-names>JD</given-names></name></person-group><article-title>Urinary tract infection: self-reported incidence and associated costs</article-title><source><italic>Annals of Epidemiology</italic></source><year>2000</year><volume>10</volume><issue>8</issue><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">11118930</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxman</surname><given-names>B</given-names></name></person-group><article-title>Recurring urinary tract infection: incidence and risk factors</article-title><source><italic>American Journal of Public Health</italic></source><year>1990</year><volume>80</volume><issue>3</issue><fpage>331</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">2305919</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamm</surname><given-names>WE</given-names></name><name><surname>Hooton</surname><given-names>TM</given-names></name></person-group><article-title>Management of urinary tract infections in adults</article-title><source><italic>New England Journal of Medicine</italic></source><year>1993</year><volume>329</volume><issue>18</issue><fpage>1328</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">8413414</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Scholes</surname><given-names>D</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women</article-title><source><italic>Journal of the American Medical Association</italic></source><year>1999</year><volume>281</volume><issue>8</issue><fpage>736</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">10052444</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschenbach</surname><given-names>DA</given-names></name><name><surname>Davick</surname><given-names>PR</given-names></name><name><surname>Williams</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Prevalence of hydrogen peroxide-producing <italic>Lactobacillus</italic> species in normal women and women with bacterial vaginosis</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>1989</year><volume>27</volume><issue>2</issue><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">2915019</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1996</year><volume>174</volume><issue>5</issue><fpage>1058</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">8896509</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>HL</given-names></name><name><surname>Richardson</surname><given-names>BA</given-names></name><name><surname>Nyange</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1999</year><volume>180</volume><issue>6</issue><fpage>1863</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">10558942</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>MAD</given-names></name><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name></person-group><article-title>The identification of vaginal <italic>Lactobacillus</italic> species and the demographic and microbiologic characteristics of women colonized by these species</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1999</year><volume>180</volume><issue>6</issue><fpage>1950</fpage><lpage>1956</lpage><pub-id pub-id-type="pmid">10558952</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Stapleton</surname><given-names>AE</given-names></name><name><surname>Hooton</surname><given-names>TM</given-names></name><name><surname>Roberts</surname><given-names>PL</given-names></name><name><surname>Fennell</surname><given-names>CL</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>Inverse association of <inline-formula><mml:math id="M8"><mml:mrow><mml:msub><mml:mtext>H</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>-producing lactobacilli and vaginal <italic>Escherichia coli</italic> colonization in women with recurrent urinary tract infections</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1998</year><volume>178</volume><issue>2</issue><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">9697725</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>TM</given-names></name><name><surname>Roberts</surname><given-names>PL</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>Effects of recent sexual activity and use of a diaphragm on the vaginal microflora</article-title><source><italic>Clinical Infectious Diseases</italic></source><year>1994</year><volume>19</volume><issue>2</issue><fpage>274</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">7986899</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>TM</given-names></name><name><surname>Hillier</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>PL</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>
<italic>Escherichia coli</italic> bacteriuria and contraceptive method</article-title><source><italic>Journal of the American Medical Association</italic></source><year>1991</year><volume>265</volume><issue>1</issue><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">1859519</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Bruce</surname><given-names>AW</given-names></name><name><surname>Fraser</surname><given-names>N</given-names></name><name><surname>Heinemann</surname><given-names>C</given-names></name><name><surname>Owen</surname><given-names>J</given-names></name><name><surname>Henning</surname><given-names>B</given-names></name></person-group><article-title>Oral probiotics can resolve urogenital infections</article-title><source><italic>FEMS Immunology &#x00026; Medical Microbiology</italic></source><year>2001</year><volume>30</volume><issue>1</issue><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11172991</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Beuerman</surname><given-names>D</given-names></name><name><surname>Heinemann</surname><given-names>C</given-names></name><name><surname>Bruce</surname><given-names>AW</given-names></name></person-group><article-title>Probiotic <italic>Lactobacillus</italic> dose required to restore and maintain a normal vaginal flora</article-title><source><italic>FEMS Immunology &#x00026; Medical Microbiology</italic></source><year>2001</year><volume>32</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11750220</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Charbonneau</surname><given-names>D</given-names></name><name><surname>Erb</surname><given-names>J</given-names></name><etal/></person-group><article-title>Oral use of <italic>Lactobacillus rhamnosus</italic> GR-1 and <italic>L. fermentum</italic> RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women</article-title><source><italic>FEMS Immunology &#x00026; Medical Microbiology</italic></source><year>2003</year><volume>35</volume><issue>2</issue><fpage>131</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">12628548</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>AW</given-names></name><name><surname>Reid</surname><given-names>G</given-names></name></person-group><article-title>Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections</article-title><source><italic>Canadian Journal of Microbiology</italic></source><year>1988</year><volume>34</volume><issue>3</issue><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">3138016</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Bruce</surname><given-names>AW</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name></person-group><article-title>Influence of three-day antimicrobial therapy and <italic>Lactobacillus</italic> vaginal suppositories on recurrence or urinary tract infections</article-title><source><italic>Clinical Therapeutics</italic></source><year>1992</year><volume>14</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">1576619</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadieux</surname><given-names>P</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Gardiner</surname><given-names>G</given-names></name><etal/></person-group><article-title>
<italic>Lactobacillus</italic> strains and vaginal ecology</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2002</year><volume>287</volume><issue>15</issue><fpage>1940</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">11960535</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>JP</given-names></name><name><surname>Cadieux</surname><given-names>PA</given-names></name><name><surname>Reid</surname><given-names>G</given-names></name></person-group><article-title>Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2003</year><volume>69</volume><issue>1</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">12513982</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Cook</surname><given-names>RL</given-names></name><name><surname>Bruce</surname><given-names>AW</given-names></name></person-group><article-title>Examination of strains of lactobacillis for properties that may influence bacterial interference in the urinary tract</article-title><source><italic>Journal of Urology</italic></source><year>1987</year><volume>138</volume><fpage>330</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">3599250</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>MAD</given-names></name><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name></person-group><article-title>The identification of vaginal <italic>Lactobacillus</italic> species and the demographic and microbiologic characteristics of women colonized by these species</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1999</year><volume>180</volume><issue>6</issue><fpage>1950</fpage><lpage>1956</lpage><pub-id pub-id-type="pmid">10558952</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasquez</surname><given-names>A</given-names></name><name><surname>Jakobsson</surname><given-names>T</given-names></name><name><surname>Ahrne</surname><given-names>S</given-names></name><name><surname>Forsum</surname><given-names>U</given-names></name><name><surname>Molin</surname><given-names>G</given-names></name></person-group><article-title>Vaginal <italic>Lactobacillus</italic> flora of healthy Swedish women</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2002</year><volume>40</volume><issue>8</issue><fpage>2746</fpage><lpage>2749</lpage><pub-id pub-id-type="pmid">12149323</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osset</surname><given-names>J</given-names></name><name><surname>Bartolome</surname><given-names>RM</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Andreu</surname><given-names>A</given-names></name></person-group><article-title>Assessment of the capacity of <italic>Lactobacillus</italic> to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>2001</year><volume>183</volume><issue>3</issue><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">11133381</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreu</surname><given-names>A</given-names></name><name><surname>Stapleton</surname><given-names>AE</given-names></name><name><surname>Fennell</surname><given-names>CL</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>Hemagglutination, adherence, and surface properties of vaginal <italic>Lactobacillus</italic> species</article-title><source><italic>Journal of Infectious Diseases</italic></source><year>1995</year><volume>171</volume><issue>5</issue><fpage>1237</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">7751699</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>L</given-names></name><name><surname>Stapleton</surname><given-names>AE</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name><name><surname>Wobbe</surname><given-names>CL</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name></person-group><article-title>Adherence of <italic>Lactobacillus</italic> crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection</article-title><source><italic>Journal of Urology</italic></source><year>2006</year><volume>176</volume><issue>5</issue><fpage>2050</fpage><lpage>2054</lpage><pub-id pub-id-type="pmid">17070251</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>MAD</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name></person-group><article-title>DNA fingerprinting of <italic>Lactobacillus crispatus</italic> strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2003</year><volume>41</volume><issue>5</issue><fpage>1881</fpage><lpage>1887</lpage><pub-id pub-id-type="pmid">12734221</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamm</surname><given-names>WE</given-names></name><name><surname>Wagner</surname><given-names>KF</given-names></name><name><surname>Amsel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Causes of the acute urethral syndrome in women</article-title><source><italic>New England Journal of Medicine</italic></source><year>1980</year><volume>303</volume><issue>8</issue><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">6993946</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Wiley</surname><given-names>DJ</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><article-title>Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis</article-title><source><italic>Infection and Immunity</italic></source><year>2006</year><volume>74</volume><issue>10</issue><fpage>5693</fpage><lpage>5702</lpage><pub-id pub-id-type="pmid">16988245</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrazzo</surname><given-names>JM</given-names></name><name><surname>Cook</surname><given-names>RL</given-names></name><name><surname>Wiesenfeld</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Women's satisfaction with an intravaginal <italic>Lactobacillus</italic> capsule for the treatment of bacterial vaginosis</article-title><source><italic>Journal of Women's Health</italic></source><year>2006</year><volume>15</volume><issue>9</issue><fpage>1053</fpage><lpage>1060</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>S</given-names></name><name><surname>Monden</surname><given-names>K</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><name><surname>Seno</surname><given-names>Y</given-names></name><name><surname>Kariyama</surname><given-names>R</given-names></name><name><surname>Kumon</surname><given-names>H</given-names></name></person-group><article-title>A pilot study evaluating the safety and effectiveness of <italic>Lactobacillus</italic> vaginal suppositories in patients with recurrent urinary tract infection</article-title><source><italic>International Journal of Antimicrobial Agents</italic></source><year>2006</year><volume>28</volume><issue>1</issue><fpage>30</fpage><lpage>34</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Randomization and followup of subjects.</p></caption><graphic xlink:href="IDOG2007-35387.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Symptoms reported by <inline-formula><mml:math id="M9"><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:math></inline-formula>2 women at clinic visits (<italic><inline-formula><mml:math id="M10"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>.05</mml:mn></mml:mrow></mml:math></inline-formula></italic> for comparison of <italic>L. crispatus</italic> CTV-05
to placebo at all visits). CTV-05, <italic>L. crispatus</italic> CTV-05; DC, abnormal
vaginal discharge; IRR, external genital or vaginal irritation; ODOR, vaginal
odor; DYS, dysuria; HA, headache; APP, abdominal or pelvic pain/cramps; LBP,
low back pain.</p></caption><graphic xlink:href="IDOG2007-35387.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Representative rep-PCR DNA fingerprints from vaginal lactobacillus isolates. MW, Molecular weight standard; C, <italic>L. crispatus</italic>; J, <italic>L. jensenii</italic>, G, <italic>L. gasseri</italic>; *, <italic>L.
crispatus</italic> CTV-05.</p></caption><graphic xlink:href="IDOG2007-35387.003"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Prevalence of vaginal <italic>Lactobacillus</italic> species at clinic visits (<italic>N</italic> = 15 for each treatment group. <inline-formula><mml:math id="M11"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>.05</mml:mn></mml:mrow></mml:math></inline-formula> for comparison of <italic>L. crispatus</italic> CTV-05 to placebo at all
visits except for <italic>L. gasseri</italic> at
1-week (<inline-formula><mml:math id="M12"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.02</mml:mn></mml:mrow></mml:math></inline-formula>)). CTV-05, <italic>L. crispatus</italic> CTV-05.</p></caption><graphic xlink:href="IDOG2007-35387.004"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">CTV-05 (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">Placebo (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">All (<italic>N</italic> = 30)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">21.5</td></tr><tr><td rowspan="1" colspan="1">Range</td><td rowspan="1" colspan="1">18&#x02013;35</td><td rowspan="1" colspan="1">19&#x02013;32</td><td rowspan="1" colspan="1">18&#x02013;35</td></tr><tr><td rowspan="1" colspan="1">UTI in the past 12 months (no.)</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Range</td><td rowspan="1" colspan="1">2&#x02013;6</td><td rowspan="1" colspan="1">2&#x02013;6</td><td rowspan="1" colspan="1">2&#x02013;6</td></tr><tr><td rowspan="1" colspan="1">Race (no.)</td></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">Asian</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Native American</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Hispanic ethnicity (no.)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Marital status (no.)</td></tr><tr><td rowspan="1" colspan="1">Single</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">Partner &#x0003e; 4
months</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Divorced</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Occupation (no.)</td></tr><tr><td rowspan="1" colspan="1">Student</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">21</td></tr><tr><td rowspan="1" colspan="1">Employed full-time</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">Unemployed</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Major medical problem ever (no.)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Pregnant ever (no.)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Abnormal Pap ever (no.)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Antimicrobial use past 30 days (no.)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Sex in the past 30 days (no.)</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">24</td></tr></tbody></table><table-wrap-foot><fn><p>CTV-05, <italic>L. crispatus</italic> CTV-05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Adverse events related to study drug use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">CTV-05 (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">Placebo (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Abnormal vaginal discharge</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">External genital irritation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">.17</td></tr><tr><td rowspan="1" colspan="1">Vaginal Candidiasis</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">.65</td></tr><tr><td rowspan="1" colspan="1">Vaginal odor</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Abdominal or pelvic cramps/abdominal pain</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Dysuria</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn><p>CTV-05, <italic>L. crispatus</italic> CTV-05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Subjects with pyuria<xref ref-type="table-fn" rid="TF1">*</xref> at follow-up clinic visits.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">CTV-05 (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">Placebo (<italic>N</italic> = 15)</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">.48</td></tr><tr><td rowspan="1" colspan="1">1-Week</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">.10</td></tr><tr><td rowspan="1" colspan="1">4-Week</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">.04</td></tr></tbody></table><table-wrap-foot><fn><p>CTV-05, <italic>L. crispatus</italic> CTV-05.</p></fn><fn id="TF1"><p>*Urine white blood cell
count &#x02265;8/mm<sup>3</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Subjects with vaginal H<sub>2</sub>O<sub>2</sub>-producing <italic>Lactobacillus</italic> detected at follow-up
clinic visits.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" colspan="5" rowspan="1">CTV-05 (<italic>N</italic> = 15)</th><th align="center" colspan="5" rowspan="1">Placebo (<italic>N</italic> = 15<xref ref-type="table-fn" rid="TF2">*</xref>)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SQ Count</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1+</td><td rowspan="1" colspan="1">2+</td><td rowspan="1" colspan="1">3+</td><td rowspan="1" colspan="1">4+</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1+</td><td rowspan="1" colspan="1">2+</td><td rowspan="1" colspan="1">3+</td><td rowspan="1" colspan="1">4+</td></tr><tr><td rowspan="1" colspan="1">Number of subjects</td><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1-Week</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4-Week</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">13<xref ref-type="table-fn" rid="TF3">**</xref>
</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">12</td></tr></tbody></table><table-wrap-foot><fn><p>CTV-05, <italic>L. crispatus</italic> CTV-05; SQ, semiquantitative.</p></fn><fn id="TF2"><p>*There were 2 women in the placebo group with no H<sub>2</sub>O<sub>2</sub>-producing
lactobacilli detected at any visit. <italic>P</italic> = 0.48 at each visit for comparison of presence or absence of H<sub>2</sub>O<sub>2</sub>-producing lactobacilli in the <italic>L. crispatus</italic> CTV-05 and Placebo groups.</p></fn><fn id="TF3"><p>**All 15 subjects had
positive vaginal cultures. Semi-quantitative
data missing for 2.</p></fn></table-wrap-foot></table-wrap></floats-group></article>